Switching From Found to PlexusDx: 2026 Cost and Service Differences

Last reviewed: September 6, 2026 Last updated: September 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

PlexusDx charges $189 per month for compounded semaglutide injection on a month-to-month plan, billed calendar monthly (12 charges per year); Found charges $289 per month for the same medication on its monthly cash-pay plan, billed every four weeks (13 charges per year). Over 12 months, PlexusDx costs $2,268 compared to Found's $3,757—a difference of $1,489 annually for month-to-month plans. Both programs require a provider to approve your prescription; neither guarantees eligibility or a specific medication. Found includes an app with 24/7 care-team access and AI lifestyle coaching; PlexusDx includes a free Doctor of Pharmacy check-in and offers optional genetic testing ($99 for program members). Found offers insurance billing and a broader medication formulary; PlexusDx is cash-only, offers oral and microdose formats, and charges the same price at every dose. If predictable calendar billing, lower month-to-month cost, and oral or microdose options matter more than app-based coaching, PlexusDx delivers a measurable cost advantage. If you prefer insurance billing, app-guided accountability, or access to branded GLP-1s and adjunct medications through one platform, Found's model may fit better despite the higher cash price.

At-a-glance comparison: Found vs PlexusDx cash-pay GLP-1

Normalized 12-month cost: Found vs PlexusDx semaglutide injection

Found bills cash-pay plans every four weeks, creating 13 charges per year instead of 12 calendar months. PlexusDx bills calendar monthly for 12 charges annually. To compare like-for-like, we calculate the effective annual cost and monthly average for both brands' semaglutide injection plans.

Found month-to-month cash-pay semaglutide: $289 per charge × 13 charges = $3,757 per year, or $313.08 effective monthly (our calculation, captured 2026-09-04).

PlexusDx month-to-month semaglutide injection: $189 per month × 12 months = $2,268 per year, or $189 effective monthly (captured 2026-09-04).

Annual difference: $3,757 − $2,268 = $1,489 saved by switching to PlexusDx on month-to-month plans (our calculation).

Found offers a 12-month prepaid option that reduces the semaglutide per-month average to $169 ($2,028 paid upfront for 48 weeks, captured 2026-09-04). PlexusDx's longest commitment is six months at $149 per month. Assuming two consecutive six-month cycles, PlexusDx totals $1,788 annually ($149 × 12), compared to Found's $2,028 prepaid—a $240 annual difference favoring PlexusDx (our calculation).

All dollar figures captured 2026-09-04; annual totals and effective monthly rates are our calculation. Found's 12-month figure requires full upfront payment; PlexusDx six-month assumes two consecutive cycles billed calendar monthly.

Tirzepatide injection cost comparison

Found month-to-month tirzepatide: $359 per charge × 13 charges = $4,667 per year, or $388.92 effective monthly (our calculation, captured 2026-07-20).

PlexusDx month-to-month tirzepatide injection: $289 per month × 12 months = $3,468 per year, or $289 effective monthly (captured 2026-09-04).

Annual difference: $4,667 − $3,468 = $1,199 saved by switching to PlexusDx month-to-month (our calculation).

Found's 12-month prepaid tirzepatide plan is listed at a $239 per-month average, implying approximately $3,107 upfront for 48 weeks (our calculation from Found's published rate structure). PlexusDx six-month tirzepatide is $249 per month; two consecutive cycles total $2,988 annually, a $119 advantage over Found's estimated prepaid option (our calculation).

Found's 12-month tirzepatide upfront amount estimated from published per-month average; PlexusDx six-month assumes two consecutive cycles. All figures captured 2026-07-20 to 2026-09-04.

Service model differences: coaching and app vs genetics and PharmD support

Found includes the Found app with 24/7 access to its care team, personalized care plans, healthy-habits guidance, and "Aimee," an AI weight-loss and lifestyle concierge (captured 2026-09-04). The platform is designed around behavioral accountability and guided progress tracking. Board-certified clinicians prescribe medications; the app layer provides daily engagement between clinical touchpoints.

PlexusDx includes a free Doctor of Pharmacy check-in and offers an optional genetic test at $99 for program members ($298 standalone, captured 2026-07-20). The test analyzes genetic variants that may influence medication metabolism; a licensed clinician interprets results and decides whether they inform your prescription. PlexusDx does not provide an app, AI coaching, or 24/7 messaging; the service model centers on clinical decision support rather than behavioral scaffolding. The test does not select or predict a medication—your provider decides based on all available clinical information.

If daily check-ins, habit tracking, and on-demand messaging help you stay consistent, Found's app infrastructure delivers structured support that PlexusDx does not replicate. If you prefer to manage adherence independently and value genetic insight into drug metabolism, PlexusDx offers that option at a lower base cost. Neither model guarantees weight-loss results or side-effect outcomes; both require you to follow your provider's dosing instructions and report adverse reactions promptly.

Medication availability: injectable-only at Found, oral and microdose at PlexusDx

Found's cash-pay GLP-1 formulary includes compounded semaglutide and tirzepatide injections, plus Foundayo (orforglipron, an oral non-peptide GLP-1 receptor agonist). Found also prescribes branded GLP-1s—Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza—and adjunct agents including metformin, topiramate, zonisamide, and Contrave, billed separately from the cash-pay medication plan (captured 2026-09-04). Compounded formats are injectable only; no compounded oral semaglutide or tirzepatide is listed.

PlexusDx offers compounded semaglutide and tirzepatide in both injectable and oral capsule formats, plus a microdose GLP-1 injection at $129 per month month-to-month (captured 2026-09-04). Oral semaglutide costs $289 month-to-month (same as tirzepatide injection); oral tirzepatide costs $349 month-to-month. The microdose option delivers a sub-therapeutic GLP-1 dose intended for maintenance or taper scenarios; it is not a first-line weight-loss prescription. PlexusDx does not offer branded GLP-1s, adjunct medications, or insurance billing.

If you want insurance coverage, access to branded drugs, or a broader medication toolkit managed through one provider, Found's formulary and billing flexibility are material advantages. If you want an oral format to avoid injections or a microdose option for long-term maintenance, PlexusDx provides those routes at a lower base cost. A licensed clinician at either program decides which medication and dose are appropriate; patient preference for route of administration informs but does not determine the prescription.

Billing cadence and budget predictability

Found's every-four-weeks billing cycle produces 13 charges per year, landing on different calendar dates each cycle. A $289 monthly charge becomes $3,757 annually instead of $3,468 (12 × $289). For budgeting against fixed monthly income or expense tracking, this cadence requires adjusting your expected charge date each cycle (captured 2026-07-20).

PlexusDx bills calendar monthly on the same date each month, producing exactly 12 charges per year. A $189 charge remains $189 × 12 = $2,268 annually with no extra cycle. If you reconcile expenses monthly or align health spending with a monthly budget, PlexusDx's calendar cadence matches standard financial planning (captured 2026-07-20).

Both programs accept HSA and FSA payment (Found confirmed, captured 2026-07-20; PlexusDx standard practice). Neither charges a separate membership fee on its cash-pay track. Found's insurance track charges $99 per month effective (annual prepaid) or $199 monthly, covering provider visits; typical copays run about $30 per visit, and medications are billed separately through insurance (captured 2026-09-04). PlexusDx does not offer insurance billing; all costs are transparent cash prices with no copay variability.

Review sentiment and reported service experience

PlexusDx holds a 4.3-star rating on Trustpilot, with 79 percent of reviews at five stars and 83 percent at four stars or higher (captured September 9, 2026). Found holds a 4.1-star rating with approximately 732 reviews on Trustpilot (captured September 4, 2026). Both platforms show majority-positive feedback; neither exhibits a pattern of severe or unresolved complaints in the captured review sample. Individual reports on both platforms mention variability in response times and occasional shipping delays, common themes across telehealth weight-management services. No systemic red flags—fraudulent billing, widespread eligibility denials after payment, or unaddressed adverse-event reports—appear in the evidence for either program.

Review ratings reflect aggregated user experience and do not predict your individual outcome. Service quality, clinician responsiveness, and prescription appropriateness vary by patient and clinical context. If you require high-touch daily support, Found's 24/7 care-team access and app infrastructure may deliver more frequent touchpoints than PlexusDx's PharmD check-in model. If you value cost predictability and genetic decision support over daily engagement, PlexusDx's structure aligns with that priority. Neither rating guarantees eligibility, medication efficacy, or absence of side effects.

Cancellation, refunds, and commitment terms

Found states "full refund if you're not clinically eligible" and "you can cancel anytime in its app" (captured 2026-07-20). Multi-month prepaid plans lock in a lower per-month rate but require upfront payment; the refund policy's application to prepaid plans after clinical approval is not specified in the captured evidence. Confirm refund terms for 12-month prepaid commitments at enrollment if you are considering that structure.

PlexusDx operates month-to-month with no stated long-term commitment on its monthly plans; three-month and six-month options require payment for the selected term but deliver a lower per-month rate. Cancellation and refund terms for multi-month PlexusDx plans are not detailed in the captured evidence. If you want maximum flexibility to stop without financial penalty, confirm each program's cancellation and prorated-refund policies at intake.

Neither program guarantees uninterrupted medication supply, dose escalation, or continuation beyond the initial prescription period. GLP-1 availability, clinical appropriateness, and individual tolerance inform whether a provider renews or adjusts your prescription. Plan for the possibility that your provider may recommend discontinuation, dose reduction, or a switch to another medication based on your response and side-effect profile.

Switch considerations: transferring your prescription and dosing continuity

Switching from Found to PlexusDx requires a new intake, provider review, and prescription. PlexusDx cannot transfer Found's prescription directly; a PlexusDx-affiliated clinician must independently determine whether a GLP-1 prescription is appropriate for you and, if so, at what starting or continuation dose. If you are currently stable on a specific dose of semaglutide or tirzepatide at Found, communicate that dose and your response during the PlexusDx intake. The PlexusDx provider will decide whether to match, reduce, or escalate your dose based on clinical judgment, your tolerance history, and your weight-management goals.

Plan for the possibility of a gap between your last Found shipment and your first PlexusDx shipment. Neither program guarantees same-day approval or next-day shipping. If continuity matters—particularly if you experience rebound appetite or weight regain when GLP-1 is interrupted—schedule your PlexusDx intake before your final Found refill runs out, and confirm the expected approval and shipping timeline during onboarding.

Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies. Found also uses compounded GLP-1s for its cash-pay track; the same FDA framework applies. Compounded semaglutide and tirzepatide are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound, even when the active pharmaceutical ingredient is identical, because compounded preparations do not undergo the same manufacturing oversight or bioequivalence testing.

Choose Found if…

• You want 24/7 access to a care team, daily habit tracking, and AI-guided lifestyle coaching integrated into one app.
• You prefer insurance billing and are willing to pay $99–$199 per month for visit coverage plus separate medication costs through your insurance.
• You want access to branded GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) and adjunct medications (metformin, topiramate, Contrave) managed by the same provider group.
• You are comfortable with a four-week billing cycle that produces 13 charges annually and are prepared for the higher effective monthly cost on cash-pay plans.
• You do not require oral GLP-1 formats or microdose options for maintenance, and injectable semaglutide or tirzepatide meets your clinical needs.

Choose PlexusDx if…

• You want the lowest month-to-month cash price for compounded semaglutide injection ($189) or tirzepatide injection ($289), billed predictably on the same calendar date each month.
• You prefer oral GLP-1 capsules to avoid injections, or you want a microdose maintenance option at $129 per month.
• You value genetic testing ($99 for members) to inform your provider's medication and dose decisions, even though the test does not guarantee a specific prescription.
• You are comfortable managing adherence and behavioral habits independently, without daily app check-ins or AI coaching.
• You want no membership fee, transparent all-in pricing, and the same cost at every dose level your provider prescribes.

Methodology and freshness

Pricing, inclusions, billing cadence, and formulary details for Found and PlexusDx were captured between July 20, 2026, and September 4, 2026, from each program's public website, checkout flows, and published plan documentation. Found's cash-pay semaglutide month-to-month rate ($289), tirzepatide rate ($359), and 12-month prepaid averages ($169 semaglutide, $239 tirzepatide) were verified across multiple sources on September 4, 2026. PlexusDx pricing—semaglutide injection $189/$169/$149, tirzepatide injection $289/$269/$249, oral semaglutide $289, oral tirzepatide $349, microdose $129—was verified September 4, 2026. Review ratings (Found 4.1 stars/~732 reviews, PlexusDx 4.3 stars/79% five-star) were captured from Trustpilot on September 9, 2026.

Annual cost calculations and effective monthly rates are our calculations, derived by multiplying stated per-charge prices by billing frequency (13 charges for Found, 12 for PlexusDx) and dividing annual totals by 12 months. Found's 12-month tirzepatide upfront cost (~$3,107) is estimated from the published $239 per-month average, following the same prepay structure documented for semaglutide. Multi-month PlexusDx annual figures assume consecutive cycles at the stated per-month rate; no additional discount for renewal is documented.

We do not represent personal experience with either program. All claims about pricing, inclusions, billing, formulary, and policies are sourced from publicly available evidence captured on the dates noted. Programs may change rates, formularies, or terms after publication; confirm current pricing, medication availability, cancellation terms, and eligibility criteria directly with the provider before enrollment.

Frequently Asked Questions

Can I transfer my Found prescription and dose directly to PlexusDx?

No. PlexusDx requires a new clinical intake, and a PlexusDx-affiliated provider must independently determine whether a GLP-1 prescription is appropriate for you and at what dose. Communicate your current Found medication and dose during intake so the PlexusDx clinician can consider your tolerance and response history, but the provider makes the final prescribing decision based on all available clinical information.

Does PlexusDx offer the same app and coaching features as Found?

No. Found includes a mobile app with 24/7 care-team access, habit tracking, and an AI lifestyle concierge. PlexusDx provides a free Doctor of Pharmacy check-in and optional genetic testing but does not offer an app, daily coaching, or on-demand messaging. If structured behavioral support is important to your adherence, Found's model delivers more frequent touchpoints.

Will switching to PlexusDx cause a gap in my medication supply?

Possibly. Neither Found nor PlexusDx guarantees same-day approval or next-day shipping. To minimize the risk of interruption, complete your PlexusDx intake before your final Found refill runs out and confirm the expected approval and shipping timeline during onboarding. Plan for the possibility of a few days without medication while your new prescription is reviewed and shipped.

How much do I save by switching from Found month-to-month semaglutide to PlexusDx?

Found charges $289 every four weeks for cash-pay semaglutide, totaling $3,757 annually (13 charges). PlexusDx charges $189 calendar monthly, totaling $2,268 annually (12 charges). The annual difference is $1,489 in favor of PlexusDx for month-to-month plans. On multi-month commitments, Found's 12-month prepaid semaglutide ($2,028/year) costs $240 more than PlexusDx's six-month plan ($1,788/year, two cycles).

Does PlexusDx accept insurance like Found does?

No. PlexusDx is cash-only with transparent per-month pricing and no membership fee. Found offers a separate insurance track ($99–$199/month for visits, medications billed through insurance) alongside its cash-pay plans. If insurance coverage is a priority, Found's billing flexibility is an advantage; if you want predictable cash pricing with no copay variability, PlexusDx delivers that structure at a lower base cost.

Sources

• Found cash-pay pricing and plan structures, accessed July 20, 2026, and September 4, 2026, from joinfound.com.
• Found insurance-track pricing and formulary details, accessed September 4, 2026, from joinfound.com.
• PlexusDx pricing (semaglutide injection, tirzepatide injection, oral formats, microdose), inclusions, and genetic testing details, accessed July 20, 2026, and verified September 4, 2026, from plexusdx.com.
• Found and PlexusDx review ratings from Trustpilot, captured September 4, 2026.
• Compounded medication regulatory status from FDA guidance on compounding pharmacies, accessed September 2026.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.